Pinnacle raises an $89M series B for its oral peptide programs

AI Briefing

• – Pinnacle Medicines Inc. raises $89M in series B funding, co-led by LAV and Foresite Capital, with total funding now at $134M.
• – The round also saw participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and existing investor Orbimed.
• – Pinnacle Medicines is focused on developing oral peptide programs.